©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Mar 25, 2025; 14(1): 98765
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.98765
Published online Mar 25, 2025. doi: 10.5501/wjv.v14.i1.98765
Dexamethasone in coronavirus disease 2019 care: Dosage and utilization insights
Laiba Shamim, Department of Clinical Medicine, Jinnah Sindh Medical University, Karachi 75510, Sindh, Pakistan
Imshaal Musharaf, Department of Medicine, Jinnah Sindh Medical University, Karachi 75510, Sindh, Pakistan
Abdulqadir J Nashwan, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar
Author contributions: Shamim L, Musharaf I and Nashwan AJ contributed to writing the draft and critically reviewing the literature.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Abdulqadir J Nashwan, MSc, PhD, Research Scientist, Department of Nursing and Midwifery Research, Hamad Medical Corporation, Rayyan Road, Doha 3050, Qatar. anashwan@hamad.qa
Received: July 4, 2024
Revised: November 4, 2024
Accepted: November 19, 2024
Published online: March 25, 2025
Processing time: 146 Days and 7.5 Hours
Revised: November 4, 2024
Accepted: November 19, 2024
Published online: March 25, 2025
Processing time: 146 Days and 7.5 Hours
Core Tip
Core Tip: This editorial evaluates a meta-analysis comparing high-dose and low-dose dexamethasone in the treatment of coronavirus disease 2019 (COVID-19) patients. The study reveals no significant differences in adverse effects and mortality between the dosing regimens. In line with the current guidelines, the study favors using low-dose dexamethasone but highlights the call for additional research on high-dose dexamethasone’s benefits. The study includes limitations such as a lack of long-term data and heterogeneity of the included studies. It is crucial to address these gaps in the future to optimize treatment strategies for COVID-19.